Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03878446 · ClinicalTrials.gov registry record · Phase 2
A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day
A Phase 2 study of Short Stature Children Born Small for Gestational Age (SGA), sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 20
- Study locations
NCT03878446 is a Phase 2 study of Short Stature Children Born Small for Gestational Age (SGA) that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 62 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT03878446, a Phase 2 study of Short Stature Children Born Small for Gestational Age (SGA), is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study compares 2 medicines used for the treatment of children who are born small and who stayed small: somapacitan given once a week (a new medicine) and Norditropin® given once a day (the medicine doctors can already prescribe). Participants will either get somapacitan or Norditropin® - which treatment is decided by chance. Both participants and the study doctor will know which treatment the participants get. The study will last for 5 years. Participants will take either an injection once every week or once every day.
Conditions Studied
Interventions
- DRUG Somapacitan
- DRUG Norditropin®
Study Locations (20)
Other
- CHU Bab El Oued Pediatrics Dept - Algiers
- Endo and Diab Dept El Oued - Algiers
- endocrino-diabetology department, Hospital IBN BADIS. - Constantine
- Med. Univ. Graz -Klinische Abteilung f. Allgemeine Pädiatrie - Graz
- LKH Salzburg- Univ. Klinik f. Kinder- und Jugendheilkunde - Salzburg
New York
- NYU Langone Hospital-LI - Garden City
- NYU Langone Hospital-LI - Mineola
- Icahn Sch of Med-Mt Sinai Hosp - New York
Minnesota
- Univ of Minnesota M.C.H. - Minneapolis
- Children's Minnesota - Saint Paul
New Jersey
- Goryeb Children's Hospital - Morristown
- Rutgers-Rwjms - New Brunswick
Alabama
- Univ of AL at Birmingham_BRM - Birmingham
California
- Children's Hosp Of Orange - Orange
Idaho
- St. Luke's Children's Endo - Boise
Ohio
- CCHMC_Cinc - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2019-07-04 |
| Est. Completion | 2026-12-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03878446
The ClinicalTrials.gov registry entry for NCT03878446 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Short Stature Children Born Small for Gestational Age (SGA) appearing as the primary indexed condition, and to 2 interventions - of which Somapacitan is the first listed.
NCT03878446 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, New York, Minnesota.
Frequently Asked Questions
What is clinical trial NCT03878446 about?
NCT03878446 is a clinical study titled "A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day". The study compares 2 medicines used for the treatment of children who are born small and who stayed small: somapacitan given once a week (a new medicine) and Norditropin® given once a day (the medicine doctors can already prescribe). Participants will either get somapacitan or Norditropin® - which ...
What is the current status of trial NCT03878446?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2019-07-04. Estimated completion is 2026-12-23.
What conditions does trial NCT03878446 study?
This clinical trial studies the following conditions: Short Stature Children Born Small for Gestational Age (SGA).
What interventions are being tested in trial NCT03878446?
The interventions under investigation include: Somapacitan (DRUG), Norditropin® (DRUG).
Who is sponsoring clinical trial NCT03878446?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03878446 being conducted?
This trial has 20 study locations across Alabama, California, Idaho, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.